Max Power @MaxPowerNGS tweet - My theory for the past couple months is the following: 1) multiple bidders for Fabry based on exceptional data 2) SM trying to bundle package of Fabry+HemoA+other GT targets, but this is less appealing based on HemoA durability questions. GT is no longer core to $SGMO

Max Power

@MaxPowerNGS

2 months

My theory for the past couple months is the following: 1) multiple bidders for Fabry based on exceptional data 2) SM trying to bundle package of Fabry+HemoA+other GT targets, but this is less appealing based on HemoA durability questions. GT is no longer core to $SGMO

Manal Mehta

@mehtamanal

2 months

I just wish someone who has kicked the tires on $SGMO #Fabry data would come out and say: here’s why it isn’t interesting. I can accept defeat on trial failure. But the company’s representations vs the inability to close a deal is truly mind boggling. @sandymacrae23 why nothing?

Replies

Max Power

@MaxPowerNGS

2 months

3) potential of Fabry is keeping bidders at the table SM is trying to extract max value for the entire $SGMO gene therapy pipeline engine. Lots of potential targets (e.g. PKU, others) that are available and could work with proven vector and strong promoter.